

North Central Cancer Treatment Group (NCCTG)

N0745, Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy  
in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma

Status Change – June 30, 2010

**NOTICE OF STATUS CHANGE**

This study is temporarily suspended to patient accrual effective immediately Wednesday, June 30, 2010.

The study is closed per protocol design for the evaluation of dose levels and adverse events in the Phase I portion of the trial.

The study will re-open to patient accrual at the completion of the evaluation and notification of the re-opening will be distributed at that time.

**Please retain this notice with the protocol.**